|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,855,246
United States Patent 9,855,246, titled "Compositions and Methods for Treating Neurological Disorders," was granted on January 2, 2018, to Biogen MA Inc. The patent claims methods and compositions for treating neurological disorders, specifically focusing on conditions associated with demyelination or neurodegeneration. The active pharmaceutical ingredient central to these claims is a sphingosine 1-phosphate (S1P) receptor modulator.
What is the core technological innovation claimed in Patent 9,855,246?
The patent's core innovation lies in the identification and application of specific S1P receptor modulators for the treatment of neurological disorders. These modulators are designed to selectively bind to and activate S1P receptors, thereby influencing immune cell trafficking and potentially promoting remyelination and neuroprotection. The claims encompass both novel chemical entities and established compounds that exhibit S1P modulating activity, provided they are formulated or administered in a manner suitable for treating the targeted neurological conditions.
Key Compound Classes and Targets
The patent broadly covers compounds that interact with S1P receptors, which are G protein-coupled receptors involved in various cellular functions, including immune cell migration, vascular integrity, and cardiac function. The described modulators are intended to cross the blood-brain barrier and exert their effects within the central nervous system (CNS).
- S1P Receptor Subtypes: While the patent does not exclusively limit itself to specific S1P receptor subtypes, it often alludes to S1P receptor subtypes 1, 3, 4, and 5, with a particular emphasis on modulation that leads to therapeutic benefit in neurological contexts.
- Therapeutic Focus: The primary therapeutic focus is on neurological disorders characterized by inflammation, demyelination, or neuronal loss. This includes, but is not limited to, multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
- Mechanism of Action: The claimed methods describe the administration of S1P receptor modulators to reduce lymphocyte infiltration into the CNS, thereby mitigating autoimmune attack on myelin sheaths. Additionally, the patent suggests potential neuroprotective and remyelinating effects.
What is the scope of the patent's claims?
Patent 9,855,246 contains a comprehensive set of claims covering pharmaceutical compositions, methods of treatment, and related technologies. The claims are structured to provide broad protection for the therapeutic use of S1P receptor modulators in neurological disorders.
Claim Categories and Examples
The patent's claims can be broadly categorized into composition of matter claims (though less prominent for novel entities within this specific patent) and method of treatment claims.
- Claim 1: This independent claim defines a method for treating a neurological disorder in a subject. It specifies administering a therapeutically effective amount of a compound that modulates S1P receptor activity. The disorder is further defined by the presence of demyelination or neurodegeneration.
- Claim 5: This claim depends on Claim 1 and specifies that the compound is a sphingosine 1-phosphate receptor modulator.
- Claim 10: This claim is directed to a pharmaceutical composition comprising a compound that modulates S1P receptor activity and a pharmaceutically acceptable carrier. The composition is for use in treating a neurological disorder associated with demyelination or neurodegeneration.
- Dependent Claims: Numerous dependent claims further refine the scope by specifying:
- Particular neurological disorders (e.g., multiple sclerosis, optic neuritis, transverse myelitis).
- Specific types of S1P receptor modulators (e.g., S1P1 agonists, antagonists, or partial agonists).
- Dosage regimens and routes of administration.
- The presence of specific patient populations or disease biomarkers.
Comparison to Existing Technologies: The claims differentiate themselves from general immunomodulatory therapies by focusing on the specific mechanism of S1P receptor modulation and its application within the CNS. They aim to capture therapies that leverage this pathway for neurological benefits, distinct from treatments targeting other immune pathways or solely symptomatic relief.
What is the current patent landscape for S1P receptor modulators in neurological therapies?
The patent landscape for S1P receptor modulators in neurological therapies is highly active and competitive. Several pharmaceutical companies hold patents related to S1P modulators, with a significant number targeting multiple sclerosis. Patent 9,855,246, assigned to Biogen, is situated within this competitive environment.
Key Players and Patented Compounds
Biogen has been a significant player in this space, notably with its drug fingolimod (Gilenya). Other companies have developed or are developing S1P modulators with varying receptor selectivity profiles.
- Biogen: Holds foundational patents related to fingolimod and its uses. Patent 9,855,246 likely builds upon this foundation, potentially covering new compounds or broader methods of use.
- Other Major Companies: Companies like Bristol Myers Squibb (ozanimod), Novartis (siponimod), and Merck KGaA (sitagliptin, though not for MS) are also active in the S1P modulator space, each with their own patented compositions and methods of treatment for various indications.
- Emerging Players: Smaller biotechs and academic institutions are also contributing to patent filings, exploring novel S1P modulator structures and therapeutic applications.
Patent Exclusivity and Generics
The expiration of key patents for S1P modulators, such as those covering fingolimod, opens the door for generic competition. However, new patents like 9,855,246 can extend market exclusivity for Biogen or its licensees by covering next-generation compounds or improved treatment methods. The strength and breadth of such patents are critical for maintaining market position.
Patent Portfolio Analysis: A thorough analysis would involve mapping the claim scope of 9,855,246 against the claims of other active patents in the S1P modulator and neurological disorder space. This includes evaluating:
- Freedom to Operate: Whether developing a new S1P modulator or treatment method would infringe existing patents.
- Patentability: The novelty and non-obviousness of new S1P modulator inventions relative to the prior art, including patent 9,855,246.
- Patent Validity: The potential for existing patents, including 9,855,246, to be challenged on grounds of obviousness, anticipation, or lack of enablement.
What are the potential business implications of Patent 9,855,246?
Patent 9,855,246 has significant implications for Biogen and its competitors in the neurological drug market. Its scope and validity will influence R&D strategies, investment decisions, and market access for S1P receptor modulators.
Strategic Considerations for Biogen
For Biogen, this patent serves as a mechanism to protect its intellectual property related to S1P receptor modulators and their application in neurological disorders.
- Market Exclusivity: It can extend the period of market exclusivity for specific S1P modulators or treatment paradigms, thereby safeguarding revenue streams.
- Pipeline Development: The patent's claims may guide the development of new S1P modulators with improved efficacy, safety profiles, or expanded therapeutic indications.
- Licensing Opportunities: Biogen could leverage this patent for licensing agreements, allowing other companies to utilize its patented technology in exchange for royalties.
Implications for Competitors
Competitors must carefully navigate the claims of Patent 9,855,246 to avoid infringement.
- R&D Direction: Companies developing S1P modulators must ensure their compounds and methods do not fall within the scope of this patent. This may necessitate focusing on compounds with different S1P receptor selectivity profiles or novel mechanisms of action.
- Litigation Risk: Potential infringement could lead to costly patent litigation. Competitors may seek to challenge the validity of the patent or design around its claims.
- Market Entry Barriers: The patent can act as a barrier to entry for new S1P modulator therapies aimed at the neurological disorder market, particularly if Biogen actively enforces its patent rights.
Investment Perspective: For investors, the existence and strength of Patent 9,855,246 are factors in assessing the long-term commercial viability of S1P modulator therapies developed by Biogen or its licensees. It influences the projected revenue potential and competitive advantage of companies operating in this therapeutic area.
Key Takeaways
United States Patent 9,855,246, granted to Biogen MA Inc., protects methods and compositions for treating neurological disorders using sphingosine 1-phosphate (S1P) receptor modulators. The patent claims methods of treatment and pharmaceutical compositions that target demyelination or neurodegeneration, focusing on the mechanism of modulating S1P receptor activity. The landscape for S1P modulators in neurology is highly competitive, with Biogen being a key innovator. This patent contributes to Biogen's intellectual property portfolio, potentially extending market exclusivity and guiding future R&D, while requiring competitors to carefully navigate its scope to avoid infringement or design around its claims.
Frequently Asked Questions
-
What specific neurological disorders are covered by the claims in Patent 9,855,246?
The patent broadly covers neurological disorders characterized by demyelination or neurodegeneration. Specific examples often cited or implied include multiple sclerosis, and other related conditions like optic neuritis and transverse myelitis, as well as neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
-
Does Patent 9,855,246 claim novel chemical compounds, or is it focused on methods of using known compounds?
While the patent may encompass novel S1P receptor modulators, its claims are also structured to cover methods of using known compounds that exhibit S1P modulating activity, provided they are applied for the treatment of the specified neurological disorders. The strength of the patent often lies in its method-of-treatment claims.
-
How does Patent 9,855,246 differ from Biogen's earlier patents on S1P modulators, such as those related to fingolimod?
Patent 9,855,246 likely builds upon earlier foundational patents. It may claim new, improved, or structurally distinct S1P modulators, or it could broaden the scope of claimed methods of treatment to encompass a wider range of neurological conditions or administration protocols than previously covered. A detailed claim-by-claim comparison is necessary for precise differentiation.
-
What is the typical duration of market exclusivity granted by a U.S. drug patent like 9,855,246?
A standard U.S. utility patent provides 20 years of protection from the filing date. However, for pharmaceuticals, additional exclusivity periods can be granted through mechanisms like Hatch-Waxman Act extensions (Patent Term Extension) and pediatric exclusivity, which can extend market protection beyond the original 20-year term.
-
Can competitors develop S1P receptor modulators for neurological disorders if Patent 9,855,246 is still in force?
Competitors can develop S1P receptor modulators, but they must ensure their products and methods do not infringe the claims of Patent 9,855,246. This often involves designing around the patent's scope, for example, by developing compounds with different S1P receptor selectivity profiles or targeting different therapeutic indications not covered by the patent. A freedom-to-operate analysis is crucial.
Citations
[1] Biogen MA Inc. (2018). Sphingosine 1-phosphate receptor modulators for treating neurological disorders. U.S. Patent 9,855,246. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
